×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
ChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns with EPS Projections, Misses Revenue Estimates
Yahoo Finance
Insights into ChromaDex's First Quarter Financial Performance and Strategic Initiatives.
6 days ago
ChromaDex First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall Street
ChromaDex ( NASDAQ:CDXC ) First Quarter 2024 Results Key Financial Results Revenue: US$22.2m (down 1.8% from 1Q 2023...
6 days ago
ChromaDex Corporation Reports First Quarter 2024 Financial Results
Business Wire
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024. First Quarter 2024 Financial and Recent...
1 week ago
ChromaDex (NASDAQ:CDXC) Stock Rating Reaffirmed by HC Wainwright
Defense World
HC Wainwright restated their buy rating on shares of ChromaDex (NASDAQ:CDXC – Free Report) in a research note issued to investors on...
3 days ago
ChromaDex: Q1 Earnings Snapshot
Houston Chronicle
LOS ANGELES (AP) — LOS ANGELES (AP) — ChromaDex Inc. (CDXC) on Wednesday reported a...
1 week ago
NutraWomen Wednesday: Mona Rosene, Global Director of Scientific Affairs, ChromaDex
NutraIngredients-USA.com
After suffering from eating disorders for decades, Mona Rosene, global director of scientific affairs at Chromadex, said she turned her pain...
2 weeks ago
HC Wainwright Equities Analysts Reduce Earnings Estimates for ChromaDex Co. (NASDAQ:CDXC)
MarketBeat
ChromaDex Co. (NASDAQ:CDXC - Free Report) - Research analysts at HC Wainwright decreased their Q4 2024 EPS estimates for shares of ChromaDex...
3 days ago
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
Yahoo Finance
LOS ANGELES, April 25, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy...
3 weeks ago
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
Business Wire
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that...
3 weeks ago
Roth Capital Research Analysts Lower Earnings Estimates for ChromaDex Co. (NASDAQ:CDXC)
Defense World
Read Roth Capital Research Analysts Lower Earnings Estimates for ChromaDex Co. (NASDAQ:CDXC) at Defense World.
5 days ago